General

Cell Line
hPSCreg name	CBIGi027-A-1
Cite as: When citing this cell line, please use the hPSCreg name (see Naming Tool ) and the corresponding Research Resource ID (RRID).	CBIGi027-A-1
Alternative name(s)	IPSC0039, LRRK2 G2385R (CBIGi027) correction
Cell line type	Human induced pluripotent stem cell (hiPSC)
Similar lines	No similar lines found.
Last update	1st April 2025
Notes	Isogenic control for CBIGi027-A.
User feedback show/hide	Written by on Delete No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG) Contact: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG)
Distributors	Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG)
Derivation country	Canada
External Databases
BioSamples	SAMEA117966083
General Information
* Is the cell line readily obtainable for third parties?	Yes Research use: allowed Clinical use: not allowed Commercial use: not allowed
Subclone of	CBIGi027-A

Donor Information

General Donor Information
Sex	female
Phenotype and Disease related information (Donor)
Diseases	A disease was diagnosed. Parkinson Disease Synonyms Parkinson Disease Parkinson's disease Parkinson's Disease Genetic variants LRRK2 (target)
External Databases (Donor)
BioSamples	SAMEA117965670

Ethics

Also have a look at the ethics information for the parental line CBIGi027-A .

For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General
The source cell information can be found in the parental cell line CBIGi027-A.
Passage number reprogrammed	P11
Reprogramming method
Vector type	Non-integrating
Vector	Episomal
Is reprogramming vector detectable?	Unknown
Vector free reprogramming
Other
Derived under xeno-free conditions	Unknown
Derived under GMP?	Unknown
Available as clinical grade?	Unknown

Culture Conditions

Surface coating	Matrigel/Geltrex
Passage method	Enzyme-free cell dissociation Gentle Cell Dissociation Reagent
O2 Concentration	21 %
CO2 Concentration	5 %
Medium	mTeSR™ 1 EDDU-002-002_iPSC_Culture_cPDF_v2_0.pdf
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?	Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?	No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?	Yes

Characterisation

Analysis of Undifferentiated Cells

Marker Expression

Marker	Expressed	Immunostaining	RT-PCR	Flow Cytometry	Enzymatic Assay	Expression Profiles
NANOG	Yes
TRA 1-60	Yes
SSEA-4	Yes
POU5F1 (OCT-4)	Yes

Microbiology / Virus Screening
HIV 1	Negative
HIV 2	Negative
Hepatitis B	Negative
Hepatitis C	Negative
Mycoplasma	Negative

Genotyping

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?	Yes Normal, 46 XX Passage number: P11 Karyotyping method: G-Banding
Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications

Parkinson Disease Synonyms Parkinson Disease Parkinson's disease Parkinson's Disease Genetic modifications LRRK2 (target) Type of modification Isogenic modification Is the modification homozygous or heterozygous? Heterozygous Free text After CRISPR/Cas9 editing, DNA Sanger sequence confirms that the wt codon GGG (Gly, G) has replace the mutant RGA (Arg, R ), correcting the missense mutation G2385R. *Note that four silent mutations were introduced in the corrected allele (heterozygous) around the target codon. How has the target locus been modified? Repaired